1-9 of 9
Fumihiko Nakao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The XPO7/Npat Axis Inactivation Is a Therapeutic Vulnerability for TP53 -Mutated AML

Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Seishi Ogawa, Takahiro Maeda, Koichi Akashi
Journal: Blood
Blood (2023) 142 (Supplement 1): 2741.
https://doi.org/10.1182/blood-2023-188986
Published: 2023
Journal Articles

Genome-Wide CRISPR/Cas9 Screens Identify DDX19A/DDX19B As a Critical Regulator of Intrinsic Apoptosis By Regulating MCL1 mRNA Cellular Localization

Tatsuya Terasaki, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Hiroshi Imanaga, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koshi Akahane, Takeshi Inukai, Koichi Akashi, Takahiro Maeda
Journal: Blood
Blood (2023) 142 (Supplement 1): 1445.
https://doi.org/10.1182/blood-2023-182620
Published: 2023
Journal Articles

The XPO7/Npat Axis Is a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, Takuji Yamauchi, Fumihiko Nakao, Jumpei Nogami, Seishi Ogawa, Koichi Akashi, Takahiro Maeda
Journal: Blood
Blood (2022) 140 (Supplement 1): 91–92.
https://doi.org/10.1182/blood-2022-168650
Published: 2022
Journal Articles

A Genome-Wide CRISPR-Cas9 Screen Reveals GATOR1 Complex Is a Critical Regulator of Glucocorticoid Sensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Hiroshi Imanaga, Yuichiro Semba, Kensuke Sasaki, Kiyoko Miyata, Takuji Yamauchi, Tatsuya Terasaki, Fumihiko Nakao, Shigeki Hirabayashi, Jumpei Nogami, Koichi Akashi, Takahiro Maeda
Journal: Blood
Blood (2022) 140 (Supplement 1): 5979.
https://doi.org/10.1182/blood-2022-164647
Published: 2022
Journal Articles

Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda
Journal: Blood
Blood (2022) 139 (5): 748–760.
https://doi.org/10.1182/blood.2021012976
Published: 2022
Includes: Supplemental data
Journal Articles

Genome-Wide CRISPR-Cas9 Screen Identifies Rationally Designed Combination Therapies Relevant for CRLF2-Rearranged Ph-like ALL

Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda
Journal: Blood
Blood (2021) 138 (Supplement 1): 2257.
https://doi.org/10.1182/blood-2021-152027
Published: 2021
Journal Articles

Paics, a De Novo Purine Synthetic Enzyme, Is a Novel Target for AML Therapy

Takuji Yamauchi, MD PhD, Kohta Miyawaki, MD, Yuichiro Semba, MD PhD, Fumihiko Nakao, MD, Takeshi Sugio, MD PhD, Kensuke Sasaki, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Simon Osborne, PhD, Luca Pinello, PhD, Deborah Taylor, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1390.
https://doi.org/10.1182/blood-2019-127047
Published: 2019
Journal Articles

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, MD PhD, Takuji Yamauchi, MD PhD, Fumihiko Nakao, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Luca Pinello, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3784.
https://doi.org/10.1182/blood-2019-129623
Published: 2019
Journal Articles

CRISPR-Cas9 Screen Identifies Me2 , a Mitochondrial Malic Enzyme, As a Molecule Relevant for MCL1 Inhibitor Resistance in AML

Fumihiko Nakao, MD, Takuji Yamauchi, MD PhD, Yuichiro Semba, MD PhD, Jumpei Nogami, PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 912.
https://doi.org/10.1182/blood-2019-129237
Published: 2019